Published in Gastroenterology on November 01, 2004
Use of targeted glycoproteomics to identify serum glycoproteins that correlate with liver cancer in woodchucks and humans. Proc Natl Acad Sci U S A (2005) 2.70
A lymphotoxin-driven pathway to hepatocellular carcinoma. Cancer Cell (2009) 2.64
Frequency of elevated hepatocellular carcinoma (HCC) biomarkers in patients with advanced hepatitis C. Am J Gastroenterol (2011) 1.20
Expression of Sox2 and Oct4 and their clinical significance in human non-small-cell lung cancer. Int J Mol Sci (2012) 1.15
Decreased survival and hepato-renal pathology in mice with C-terminally truncated GP73 (GOLPH2). Int J Clin Exp Pathol (2008) 1.15
Diagnostic value of glypican-3 in serum and liver for primary hepatocellular carcinoma. World J Gastroenterol (2010) 1.08
Identification and confirmation of biomarkers using an integrated platform for quantitative analysis of glycoproteins and their glycosylations. J Proteome Res (2010) 1.05
Human acyl-CoA:cholesterol acyltransferase 2 gene expression in intestinal Caco-2 cells and in hepatocellular carcinoma. Biochem J (2006) 0.93
Identification of serum CCL15 in hepatocellular carcinoma. Br J Cancer (2013) 0.88
Tissue expression of Squamous Cellular Carcinoma Antigen (SCCA) is inversely correlated to tumor size in HCC. Mol Cancer (2009) 0.88
Circulating microRNA-101 as a potential biomarker for hepatitis B virus-related hepatocellular carcinoma. Oncol Lett (2013) 0.87
Circulating cell-free DNA as a predictive marker for distant metastasis of hepatitis C virus-related hepatocellular carcinoma. Br J Cancer (2007) 0.87
Identification of biomarkers for hepatocellular carcinoma using network-based bioinformatics methods. Eur J Med Res (2013) 0.84
Y-box protein-1/p18 fragment identifies malignancies in patients with chronic liver disease. BMC Cancer (2011) 0.84
Microarray-based gene expression analysis of hepatocellular carcinoma. Curr Genomics (2010) 0.83
MicroRNAs may solve the mystery of chronic hepatitis B virus infection. World J Gastroenterol (2013) 0.80
Circulating microRNA, miR-122 and miR-221 signature in Egyptian patients with chronic hepatitis C related hepatocellular carcinoma. World J Hepatol (2014) 0.80
The dynamics of glutathione species and ophthalmate concentrations in plasma from the VX2 rabbit model of secondary liver tumors. HPB Surg (2011) 0.80
Effective inhibition of xenografts of hepatocellular carcinoma (HepG2) by rapamycin and bevacizumab in an intrahepatic model. Mol Imaging Biol (2009) 0.79
Detection and identification of NAP-2 as a biomarker in hepatitis B-related hepatocellular carcinoma by proteomic approach. Proteome Sci (2008) 0.78
Clinical utility of protein induced by vitamin K absence in patients with chronic hepatitis B virus infection. Biomed Rep (2012) 0.75
Hepatocellular Carcinoma: Tumorigenesis and Prediction Markers. Gastroenterology Res (2009) 0.75
Keratin 18-deficiency results in steatohepatitis and liver tumors in old mice: A model of steatohepatitis-associated liver carcinogenesis. Oncotarget (2016) 0.75
Management of hepatitis B: summary of a clinical research workshop. Hepatology (2007) 3.40
Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology (2010) 3.35
Public health impact of antiviral therapy for hepatitis C in the United States. Hepatology (2009) 3.10
Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection. Hepatology (2002) 2.79
Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations. J Hepatol (2008) 2.66
Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. J Hepatol (2005) 2.63
Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial. Hepatology (2008) 2.44
Persistence and adherence to nucleos(t)ide analogue treatment for chronic hepatitis B. J Hepatol (2010) 2.38
Hepatitis B virus genotypes in the United States: results of a nationwide study. Gastroenterology (2003) 2.38
Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C. Gastroenterology (2002) 2.34
Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation. J Hepatol (2005) 2.26
Effect of lamivudine treatment on survival of 309 North American patients awaiting liver transplantation for chronic hepatitis B. Liver Transpl (2002) 2.25
Hepatitis C-related hepatocellular carcinoma in the United States: influence of ethnic status. Am J Gastroenterol (2003) 2.18
Hepatitis B virus genotypes: do they play a role in the outcome of HBV infection? Hepatology (2004) 2.09
Noninvasive monitoring of patients with chronic hepatitis C. Hepatology (2002) 2.08
Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial. Hepatology (2006) 2.06
Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol (2005) 2.04
Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice. Hepatology (2011) 1.98
Impact of the model for end-stage liver disease allocation policy on the use of high-risk organs for liver transplantation. Gastroenterology (2008) 1.95
HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C. Hepatology (2002) 1.88
Re-weighting the model for end-stage liver disease score components. Gastroenterology (2008) 1.83
Clinical significance of hepatitis B virus genotypes. Hepatology (2002) 1.82
Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C. Gut (2010) 1.78
Evolution of multi-drug resistant hepatitis B virus during sequential therapy. Hepatology (2006) 1.76
Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. Gastroenterology (2006) 1.76
Prevalence and significance of occult hepatitis B in a liver transplant population with chronic hepatitis C. Liver Transpl (2008) 1.72
Presence of intrahepatic (total and ccc) HBV DNA is not predictive of HBV recurrence after liver transplantation. Liver Transpl (2007) 1.64
Comparison of clinical outcomes in chronic hepatitis B liver transplant candidates with and without hepatocellular carcinoma. Liver Transpl (2007) 1.61
Outcomes in hepatitis C virus-infected recipients of living donor vs. deceased donor liver transplantation. Liver Transpl (2007) 1.58
Indications for therapy in hepatitis B. Hepatology (2009) 1.57
When to start and stop hepatitis B treatment: can one set of criteria apply to all patients regardless of age at infection? Ann Intern Med (2007) 1.48
Chronic disease management for patients with cirrhosis. Gastroenterology (2010) 1.47
Prevalence of HBV precore/core promoter variants in the United States. Hepatology (2003) 1.47
Identification and management of hepatitis C patients in primary care clinics. Am J Gastroenterol (2003) 1.45
Rapid and sensitive assays for determination of hepatitis B virus (HBV) genotypes and detection of HBV precore and core promoter variants. J Clin Microbiol (2003) 1.43
Clinical decisions. Management of incidental hepatitis C virus infection. N Engl J Med (2009) 1.42
Predicting clinical and histologic outcomes based on standard laboratory tests in advanced chronic hepatitis C. Gastroenterology (2009) 1.35
Sensitive line probe assay that simultaneously detects mutations conveying resistance to lamivudine and adefovir. J Clin Microbiol (2006) 1.25
Effectiveness of hepatitis B treatment in clinical practice. Gastroenterology (2012) 1.25
Emotional distress in chronic hepatitis C patients not receiving antiviral therapy. J Hepatol (2002) 1.19
Hepatitis B virus variants. Nat Rev Gastroenterol Hepatol (2009) 1.18
HCV RNA detection by TMA during the hepatitis C antiviral long-term treatment against cirrhosis (Halt-C) trial. Hepatology (2006) 1.13
Low risk of hepatitis B virus recurrence after withdrawal of long-term hepatitis B immunoglobulin in patients receiving maintenance nucleos(t)ide analogue therapy. Liver Transpl (2007) 1.10
A genotype-independent real-time PCR assay for quantification of hepatitis B virus DNA. J Clin Microbiol (2006) 1.08
Myopathy and neuropathy associated with nucleos(t)ide analog therapy for hepatitis B. J Hepatol (2009) 1.06
Patient decision making about organ quality in liver transplantation. Liver Transpl (2011) 1.04
Management of hepatitis B patients with antiviral resistance. Antivir Ther (2004) 1.02
Outcomes of patients with chest tube insertion for hepatic hydrothorax. Hepatol Int (2009) 1.01
Report on a single-topic conference on "Chronic viral hepatitis--strategies to improve effectiveness of screening and treatment". Hepatology (2012) 1.00
Hepatitis B virus core promoter mutations contribute to hepatocarcinogenesis by deregulating SKP2 and its target, p21. Gastroenterology (2011) 1.00
Viral factors and outcomes of chronic HBV infection. Am J Gastroenterol (2011) 0.98
Blunted cytopenias and weight loss: new correlates of virologic null response to re-treatment of chronic hepatitis C. Clin Gastroenterol Hepatol (2008) 0.98
Serum fibrosis marker levels decrease after successful antiviral treatment in chronic hepatitis C patients with advanced fibrosis. Clin Gastroenterol Hepatol (2008) 0.96
Reduction of insulin resistance with effective clearance of hepatitis C infection: results from the HALT-C trial. Clin Gastroenterol Hepatol (2010) 0.95
Emotional distress during interferon-alpha-2B and ribavirin treatment of chronic hepatitis C. Psychosomatics (2002) 0.95
Update on viral hepatitis: 2008. Curr Opin Gastroenterol (2009) 0.93
Effectiveness of interferon alpha-2b and ribavirin combination therapy in the treatment of naive chronic hepatitis C patients in clinical practice. Clin Gastroenterol Hepatol (2004) 0.92
Management of patients with hepatitis B virus-induced cirrhosis. J Hepatol (2004) 0.91
Interpretation of positive transcription-mediated amplification test results from polymerase chain reaction-negative samples obtained after treatment of chronic hepatitis C. Hepatology (2008) 0.91
Antiviral options for the treatment of chronic hepatitis B. J Antimicrob Chemother (2006) 0.91
Treatment of hepatitis B. J Gastroenterol (2002) 0.90
Cognitive function does not worsen during pegylated interferon and ribavirin retreatment of chronic hepatitis C. Hepatology (2007) 0.89
Treatment of chronic hepatitis B: who to treat, what to use, and for how long? Clin Gastroenterol Hepatol (2004) 0.88
Changes in mood states and biomarkers during peginterferon and ribavirin treatment of chronic hepatitis C. Am J Gastroenterol (2008) 0.88
[AASLD Practice Guidelines. Chronic hepatitis B: update of therapeutic guidelines]. Rom J Gastroenterol (2004) 0.88
Two distinct subtypes of hepatitis B virus-related acute liver failure are separable by quantitative serum immunoglobulin M anti-hepatitis B core antibody and hepatitis B virus DNA levels. Hepatology (2012) 0.88
Cognitive reserve and neuropsychological functioning in patients infected with hepatitis C. J Int Neuropsychol Soc (2007) 0.87
Drug insight: Nucleoside and nucleotide analog inhibitors for hepatitis B. Nat Clin Pract Gastroenterol Hepatol (2004) 0.87
HBV core promoter mutations promote cellular proliferation through E2F1-mediated upregulation of S-phase kinase-associated protein 2 transcription. J Hepatol (2013) 0.87
Outcomes of patients with hepatitis B who developed antiviral resistance while on the liver transplant waiting list. Clin Gastroenterol Hepatol (2007) 0.87
Tenofovir disoproxil fumarate: role in hepatitis B treatment. Hepatology (2006) 0.86
Does antiviral therapy prevent recurrence of hepatitis B virus–related hepatocellular carcinoma after curative liver resection? JAMA (2012) 0.85
Predicting clinical outcomes using baseline and follow-up laboratory data from the hepatitis C long-term treatment against cirrhosis trial. Hepatology (2011) 0.85
Occult hepatitis B virus infection in patients with hepatocellular carcinoma: Innocent bystander, cofactor, or culprit? Gastroenterology (2004) 0.85
Long-term efficacy of nucleoside monotherapy in preventing HBV infection in HBsAg-negative recipients of anti-HBc-positive donor livers. Hepatol Int (2010) 0.83
Hepatitis B virus genotypes, precore and core promoter variants among predominantly Asian patients with chronic HBV infection in a Canadian center. Liver Int (2006) 0.81
Is family history of liver cancer a risk factor for hepatocellular carcinoma? J Hepatol (2008) 0.81
Update on viral hepatitis: 2005. Curr Opin Gastroenterol (2006) 0.81
The dawn of a new era: transforming our domestic response to hepatitis B & C. Gastroenterology (2010) 0.81
Combination of HBIG and lamivudine-resistant mutations: a formula for trouble? Liver Transpl (2002) 0.78
Hepatitis C disease severity in living versus deceased donor liver transplant recipients: an extended observation study. Hepatology (2014) 0.78
Viral hepatitis in 2003. Curr Opin Gastroenterol (2004) 0.77
Update on viral hepatitis in 2004. Curr Opin Gastroenterol (2005) 0.77
Treatment of hepatitis B: who, when, and how? Arch Intern Med (2006) 0.77
Viral hepatitis at a crossroad. Gastroenterology (2012) 0.77
Beyond utilitarianism: a method for analyzing competing ethical principles in a decision analysis of liver transplantation. Med Decis Making (2008) 0.76
Natural history of hepatitis B and outcomes after liver transplantation. Clin Liver Dis (2003) 0.76
Liver transplantation for patients with lamivudine-resistant HBV: what is the optimal prophylactic strategy? Liver Transpl (2005) 0.75
Endpoints for clinical trials on treatment of hepatitis C. J Hepatol (2006) 0.75
Antiviral therapy for pre- and post-liver transplantation patients with hepatitis B. Liver Transpl (2007) 0.75
High-dose interferon alfa-2b and ribavirin in patients previously treated with interferon: results of a prospective, randomized, controlled trial. J Clin Gastroenterol (2002) 0.75
New pharmacologic therapies in chronic hepatitis B. Gastroenterol Clin North Am (2010) 0.75
Characteristics and outcomes of transjugular intrahepatic portosystemic shunt recipients in the VA Healthcare System. Eur J Gastroenterol Hepatol (2016) 0.75
Characteristics of US-Born Versus Foreign-Born Americans of African Descent With Chronic Hepatitis B. Am J Epidemiol (2017) 0.75